Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
What the film says
This trial is for adults with post transplant lymphoproliferative disorder, a lymphoma that can develop after an organ or stem cell transplant, that has come back or not responded to treatment.
The idea: epcoritamab is a bispecific antibody given as a shot under the skin. One end binds CD3 on T cells, and the other binds CD20 on B cells and some lymphoma cells, bringing immune cells to the cancer.
The study looks at safety and effectiveness.
This phase 1 study plans 26 patients. At the Ohio State University Comprehensive Cancer Center in Columbus, Timothy Voorhees leads it.
Public record; not medical advice.
Sources behind this film
Adults; R/R PTLD; Epcoritamab SC; bispecific CD3/CD20; Safety and effectiveness; Phase 1; 26; OSU; Timothy Voorhees
The drug
PRIMARY OBJECTIVE: I. To assess the safety of treatment with epcoritamab in subjects with PTLD. SECONDARY OBJECTIVES: I. To estimate the Objective Response Rate (ORR), defined as the clinical response (complete response [CR] + partial response [PR]) after 3 cycles of epcoritamab. II. To estimate the clinical benefit rate (CBR) in subjects with PTLD treated with epcoritamab. III.
To estimate the best objective response rate (BOR) in subjects with PTLD treated with epcoritamab. IV. To estimate the progression free survival (PFS) in subjects with PTLD treated with epcoritamab. V. To estimate the duration of complete response (DoCR) in subjects with PTLD treated with epcoritamab. VI. To estimate the overall survival (OS) in subjects with PTLD treated with epcoritamab. EXPLORATORY OBJECTIVES: I.
The study
This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell).
It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Giving epcoritamab may be safe and effective in treating patients with relapsed or refractory B-cell PTLD.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.